Prediction of the risk of coronary arterial lesions in Kawasaki disease by serum 25-hydroxyvitamin D3

Yan-Li Chen · Juan-Li Wang · Wei-Qin Li

Received: 10 January 2014 / Revised: 15 May 2014 / Accepted: 23 May 2014 / Published online: 3 June 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract Kawasaki disease (KD) is associated with the development of coronary arterial lesions (CALs) in children. We aimed to test the hypothesis that circulating 25-hydroxyvitamin D3 [25-(OH)D3] could be identified as a clinical parameter for predicting CALs secondary to KD in children. We enrolled 35 children with KD in the acute phase and measured serum 25-(OH)D3 levels in all of them, then followed up by echocardiography for CALs. Additionally, serum 25-(OH)D3 levels were obtained in 23 febrile children with respiratory tract infections and 30 healthy children. Of the 35 KD children, nine had CALs according to echocardiography and 26 did not (NCALs). Serum 25-(OH)D3 levels were not significantly different between NCALs and healthy children (49.2±23.8 versus 44.1±30.2 ng/ml; P=0.49). Serum 25-(OH)D3 levels were significantly higher in children with CALs than those without CALs (83.9±26.3 versus 49.2 ±23.8 ng/ml; P=0.001). The cutoff value of 65 ng/ml to predict subsequent CALs had a specificity of 0.73, sensitivity of 0.78, and diagnostic accuracy of 0.74.

Conclusion Serum 25-(OH)D3 levels were elevated during the acute phase in KD children who had subsequent CALs. Serum 25-(OH)D3 levels in the acute phase of KD may be used to predict subsequent CALs.

Keywords Kawasaki disease · 25-Hydroxyvitamin D3 · Coronary artery lesions

Abbreviations
CALs Coronary arterial lesions
KD Kawasaki disease

Introduction
Kawasaki disease (KD), first described in 1967 by Dr. Tomisaku Kawasaki as mucocutaneous lymph node syndrome [7], is an acute systemic vasculitis that primarily affects small- and medium-sized arteries. KD that predominantly affects children younger than 5 years is mostly a self-limiting disease, but sometimes gives rise to serious cardiac complications. Coronary arterial lesions (CALs), including dilatations and aneurysms, are identified as the most serious complications of KD. In China, approximately 8.5 to 20.6 % of KD patients develop CALs [4, 11, 12, 16, 28]. Even after high-dose immunoglobulin therapy, 5–10 % of KD children develop CALs [14]. CALs secondary to KD are associated with changes in certain biomarkers, such as platelet count, neutrophil count, plateletcrit, platelet distribution width, mean platelet volume, erythrocyte sedimentation rate, cardiac troponin I, endothelin-1, albumin, and hemoglobin [3]. In a retrospective study [2] involving 113 Chinese children, Kobayashi scoring system was applied to predict coronary arterial lesions in KD, and the results showed that the sensitivity of the Kobayashi scoring system was 0.56. Though the Kobayashi scoring system had the ability to predict the coronary arterial lesions in KD patients, the power was not high enough. Therefore, a laboratory marker in the initial acute
Adjunctive 1-alpha, 25-dihydroxyvitamin D₃ therapy and subsequently elevated 25-(OH)D₃ levels. The purpose of this study was to investigate the clinical value of serum 25-(OH) D₃ levels as a predictor of CALs in children with KD.

Material and methods

Study population

We enrolled 35 children diagnosed with KD [15] between March 2011 and July 2013 at the Affiliated Hospital of Xi’an Medical College. All the children received intravenous globulin treatment. Once Kawasaki disease is diagnosed, immunoglobulin therapy should begin within 24 h. Echocardiography was used to detect the presence of CALs during the course of the disease. Of the 35 children diagnosed with KD, nine (six boys and three girls) developed CALs based on echocardiographic results and 26 (19 boys and 7 girls) did not develop CALs (NCALs). In addition, 23 children with respiratory tract infections were included as febrile controls. These children did not have cutaneous eruption or myocardial injury and were excluded if they had abnormal myocardial enzyme levels or an abnormal electrocardiogram. Furthermore, 30 healthy children were selected as normal controls. Children with heart, lung, or kidney disease were excluded. The study was approved by the Ethics Committee of the Affiliated Hospital of Xi’an Medical College. Parental informed consent was obtained for each child enrolled in this study. There were no significant differences between the groups regarding baseline characteristics.

Measurement of serum 25-(OH)D₃ levels

Fasting blood samples (approximately 3 ml) were collected for each patient between 5 and 10 days of disease onset. The samples were centrifuged at 3,000 rpm/min for 10 min and stored at −70 °C until analysis. Serum 25-(OH)D₃ concentrations were measured using a commercially available ELISA kit (Shanghai XinLe Biological Technology Co., Ltd.) according to the manufacturer’s instructions. The same method was used to measure 25-(OH) D₃ levels in febrile children and healthy control children.

statistical analysis

Continuous data were expressed as mean±standard deviation (SD) if the values were normally distributed. Statistical comparisons of continuous variables were performed by a two-tailed Student’s t test. A χ² test was used to compare categorical variables. P<0.05 was considered statistically significant. All analyses were performed with SPSS V.17.0 (SPSS Inc, Chicago, Illinois, USA). To compare the power of serum level of 25-(OH)D₃ levels in predicting CALs, receiver-operating characteristic curves (ROCs) were plotted and areas under the curve (AUCs) were calculated.

Results

The KD cases included 26 boys and 9 girls with an age range of 4 months to 4 years. Six boys and three girls developed CALs. The febrile children group included 11 boys and 12 girls with an age range of 5 months to 4 years. The normal controls consisted of 16 boys and 14 girls with an age range of 5 months to 4 years.

Comparison of 25-(OH)D₃ levels

The mean serum 25-(OH)D₃ levels in febrile children was significantly lower than healthy children (27.9±20.6 versus 44.1±30.2 ng/ml; P=0.025). This level was not significantly different between NCALs and healthy children (49.2±23.8 versus 44.1±30.2 ng/ml; P=0.49) (Table 1). In addition, the mean serum 25-(OH)D₃ levels were significantly higher in children with CALs than those without CALs (83.9±26.3 versus 49.2±23.8 ng/ml; P=0.001).
To assess the performance of serum level of 25-(OH)D3 in predicting CALs, ROCs were plotted and the AUCs was calculated. As shown in Fig. 1, the AUC for predicting CALs of 25-(OH)D3 was 0.831. When the cutoff value of 65 ng/ml for 25-(OH)D3 based on the ROC was obtained for predicting CALs, it generated a sensitivity of 78 % and specificity of 73 %. Detailed characteristics of cutoff value of 65 ng/ml for CAL prediction were listed in Table 2.

**Discussion**

The current study showed that serum levels of 25(OH)D3 were significantly higher in KD children who developed CALs compared with children who did not develop CALs. Higher serum 25-(OH)D3 levels in the acute phase of KD was associated with an increased risk of developing CALs. A cutoff value of 65 ng/ml for 25-(OH)D3 based on the ROC was obtained for predicting CALs, it generated a sensitivity of 78 % and specificity of 73 %. Detailed characteristics of cutoff value of 65 ng/ml for CAL prediction were listed in Table 2.

To the best of our knowledge, the association of serum 25-(OH)D3 levels in the diagnosis of CALs among children with KD has not been reported, and this is the first report to identify the role of 25(OH)D3 in predicting CALs in KD. We found that serum 25-(OH)D3 levels measured in the acute phase KD was significantly higher in children with CALs than those without CALs ($P=0.001$). A 25-(OH)D3 cutoff point of 65 ng/ml had a sensitivity of 0.78 and specificity of 0.73 for predicting the development of subsequent CALs. Therefore, measurement of 25-(OH)D3 levels in the acute phase KD could be beneficial in clinical practice to identify cardiac complications. However, 25-(OH)D3 levels were not significantly different between the NCAL group and healthy children, making it difficult to be used as a parameter to exclude NCALs in KD. The mechanisms involved in the

**Table 1** Comparison of serum 25-(OH)D3 levels between different groups

| Group                              | Number | 25-(OH)D3 (ng/ml) |
|------------------------------------|--------|------------------|
| Febrile children with respiratory  | 23     | 27.9±20.2        |
| tract infections                   |        |                  |
| Healthy control                    | 30     | 44.1±30.2        |
| NCALs                              | 26     | 49.2±23.8        |
| CALs                               | 9      | 83.9±26.3        |

Values were expressed as mean±SD

*CALs* coronary arterial lesions, *NCALs* no coronary arterial lesions

*Comparing with febrile children with respiratory tract infection group: $t=2.31, P=0.025$*

*Comparing with healthy control group: $t=1.16, P=0.49$*

*Comparing with NCALs group: $t=3.68, P=0.001$*

**Table 2** Performance of 25-(OH)D3 with a cutoff level of 65 ng/ml

| Parameters                     | Value (%) |
|--------------------------------|-----------|
| Sensitivity                    | 78        |
| Specificity                    | 73        |
| Positive predictive value      | 50        |
| Negative predictive value      | 90        |
| Diagnostic accuracy            | 74        |
elevation of serum 25-(OH)D$_3$ levels in the acute phase of KD need to be explored further. The proposed mechanism includes the higher expression of VDR in T cells in KD patients than febrile children with respiratory tract infections and healthy children. Overactivated T cells likely promote 25-(OH)D$_3$ release. Therefore, more intense inflammatory response in CALs’ patients may have increased VDR expression and subsequently elevated 25-(OH)D$_3$ levels.

The newborn in China receive vitamin D supplement after day 14 of birth regularly without measurement of serum 25-(OH)D level. The dosage for under 1 year old is 500 U per day and for 1 to 2 years old is 600 U per day until 18 years old. However, due to the vitamin D preparation available in the market, almost all the children received vitamin D supplement under 2 years old and few children more than 2 years old received supplement vitamin D [26].

There were some limitations in this study. The small sample size of KD children lowered the statistical power. The high incidence of the occurrence of CALs in this study might be correlated with the small sample size. Second, the prevalence of CALs in the children directly influenced the predictive values. Further, 25-(OH)D$_3$ levels may vary according to race [18] and region [21], so caution is needed before the current results are generalized to other patients. Third, the severity of KD is classified by the severity of coronary artery dilatation. However, due to the small sample size, we did not conduct correlation analysis between the severity of CALs and 25-(OH)D$_3$ level; therefore, the relationships are still unclear between the severity of CALs and 25-(OH)D$_3$ level. Finally, since 25-(OH)D$_3$ levels were not elevated in KD children with normal coronary arteries in the current study, serum 25-(OH)D$_3$ levels may not be used to diagnose KD.

Conclusions

Serum 25-(OH)D$_3$ levels greater than 65 ng/ml in the acute phase of KD may be predictive of developing subsequent CALs; however, it may not be helpful in the diagnosis of KD. More studies are needed to confirm whether serum 25-(OH)D$_3$ levels could be used to predict CALs in KD.

Acknowledgments This work was supported by a grant from the Key Project of Social Development of Shanxi Province (2012SF2-10). We thank Medijaden Bioscience Limited for the assistance in the preparation of this manuscript.

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Cantorna MT, Zhu Y, Froicu M, Wittke A (2004) Vitamin D status, 1, 25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 80:1717S–1720S
2. Chen JJ, Liu YL (2011) Clinical values of Kobayashi scoring system in Chinese children with Kawasaki disease. Acta Med Univ Sci Technol Huazhong 40:746–749
3. Chen J, Liu Y, Liu W, Wu Z (2011) A meta-analysis of the biomarkers associated with coronary artery lesions secondary to Kawasaki disease in Chinese children. J Huazhong Univ Sci Technol Med Sci 31:705–711
4. Du ZD, Zhao D, Du J, Zhang YL, Lin Y, Liu C, Zhang T (2007) Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004. Pediatr Infect Dis J 26:449–451
5. Hewison M (2010) Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol 321:103–111
6. Kaneko K, Yoshimura K, Ohashi A, Kimata T, Shimo T, Tsuji S (2011) Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr Cardiol 32:1106–1109
7. Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 16:178–222
8. Kemmotsu Y, Saji T, Kusunoki N, Tanaka N, Nishimura C, Ishiguro A, Kawai S (2012) Serum adipokine profiles in Kawasaki disease. Mod Rheumatol 22:66–72
9. Kudo K, Hasegawa S, Suzuki Y, Hirano R, Wakiguchi H, Kitta S, Ichiyama T (2012) 1alpha,25-Dihydroxyvitamin D3 inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in human coronary arterial endothelial cells. J Steroid Biochem Mol Biol 132:290–294
10. Lee KY, Rhim JW, Kang JH (2012) Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a “protein homeostasis system”. Yonsei Med J 53:262–275
11. Li XJ, Li XJ, Li H, Xu M, Zhou M (2008) Epidemiological survey of Kawasaki disease in Sichuan province of China. J Trop Pediatr 54:111–116
12. Ma XJ, Yu CY, Huang M, Chen SB, Huang MR, Huang GY (2010) Epidemiologic features of Kawasaki disease in Shanghai from 2003 through 2007. Chin Med J (Engl) 123:2629–2634
13. Nakamura Y, Yashiro M, Watanabe M, Tajimi M, Oki I, Ojima T, Sonobe T, Yanagawa H (2004) Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 46:33–38
14. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639
15. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708–1733
16. Ng YM, Sung RY, So LY, Fong NC, Ho MH, Cheng YW, Lee SH, Mak WC, Wong DM, Yam MC, Kwok KL, Chiu WK (2005) Kawasaki disease in Hong Kong, 1994 to 2000. Hong Kong Med J 11:331–335
17. Peng H (2006) The role and molecular mechanism of 25-(OH) D3 and its receptor in the pathogenesis of Kawasaki disease. Wuhan: Huazhong University of Science and Technology, Graduate Department of Tongji Medical College
18. Scragg R, Sowers M, Bell C (2007) Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 20:713–719
19. Shimizu C, Oharaseki T, Takahashi K, Kottek A, Franco A, Burns JC (2013) The role of TGF-beta and myofibroblasts in the arteritis of Kawasaki disease. Hum Pathol 44:189–198
20. Suzuki Y, Ichiyama T, Ohsaki A, Hasegawa S, Shiraishi M, Furukawa S (2009) Anti-inflammatory effect of 1alpha,25-dihydroxyvitamin D(3) in human coronary arterial endothelial cells: implication for the treatment of Kawasaki disease. J Steroid Biochem Mol Biol 113:134–138
21. Valtuena J, Breidenassel C, Folle J, Gonzalez-Gross M (2011) Retinol, beta-carotene, alpha-tocopherol and vitamin D status in European adolescents: regional differences and variability: a review. Nutr Hosp 26:280–288
22. van de Luijtgaarden KM, Voute MT, Hoeks SE, Bakker EJ, Chonchol M, Stolker RJ, Rouwet EV, Verhagen IH (2012) Vitamin D deficiency may be an independent risk factor for arterial disease. Eur J Vasc Endovasc Surg 44:301–306
23. van Etten E, Mathieu C (2005) Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101
24. Weng KP, Hsieh KS, Huang SH, Ou SF, Lai TJ, Tang CW, Lin CC, Ho TY, Liou HH, Ger LP (2013) Interleukin-18 and coronary artery lesions in patients with Kawasaki disease. J Chin Med Assoc 76:438–445
25. White JH (2012) Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord 13:21–29
26. Wu KM (2012) Vitamin D, calcium nutrition supplement China children. J Pract Pediatr 27:165–169
27. Yin W, Wang X, Ding Y, Peng H, Liu YL, Wang RG, Yang YL, Xiong JH, Kang SX (2011) Expression of nuclear factor-kappaBp65 in mononuclear cells in Kawasaki disease and its relation to coronary artery lesions. Indian J Pediatr 78:1378–1382
28. Zhang X, Zhang Z, Liu S, Sun J (2012) Epidemiologic survey of Kawasaki disease in Jilin from 1999 through 2008. Pediatr Cardiol 33:272–279